This discussion with Program Chair Christina Y. Weng, MD, MBA, and David A Eichenbaum, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.
Drs. Weng and Eichenbaum also converse about the latest data on pipeline therapies for diabetic macular edema, including faricimab, KSI-301, and OPT-302.
Supported by an educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education LLC (Evolve).
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Christina Y. Weng, MD, MBA
Associate Professor of Ophthalmology
Fellowship Program Director
Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Cullen Eye Institute
David A. Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
Tampa, Florida
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Christina Y. Weng, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera Sciences, Allergan/AbbVie, DORC, Genentech, Novartis, Regeneron Pharmaceuticals, and Regenxbio.
David A. Eichenbaum, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, EyePoint Pharmaceuticals, Genentech, Gyroscope, IvericBio, Kodiak, Notal Vision, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu, Gemini, Genentech, Gyroscope, lonis, lvericBio, Kodiak, Mylan, NGM, Novartis, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Allergan, Bayer, DORC, EyePoint Pharmaceuticals, Genentech, and Novartis.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
